Biotech

All Articles

AstraZeneca articles data on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has shared a very early check out the performance of its internal antibody-drug conjuga...

iTeos- GSK's TIGIT celebrity shows significant enhancement

.After introducing a phase 3 launch based on positive midstage outcomes, iTeos and also GSK are ulti...

More collective FDA can easily speed up uncommon ailment R&ampD: file

.The FDA needs to be extra available and also joint to discharge a surge in commendations of uncommo...

Zenas, MBX, Bicara scalp to Nasdaq in very hot time for biotech IPOs

.It's an unusually busy Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bicara The...

Atea's COVID antiviral stops working to halt hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has actually neglected yet another COVID-19 test, yet the biotech s...

Neurocrine's quote to conserve schizophrenia prospect fails

.Neurocrine Biosciences' schizophrenia program pivot has fallen short. The biotech was actually not ...

Sanofi pays out $110M upfront for late-stage radioligand treatment

.Sanofi has made a late access to the radioligand gathering, spending 100 million euros ($ 110 thous...

F 2G increases $100M for second effort to obtain brand new antifungal to market

.After F2G's 1st attempt to acquire a new course of antifungal to market was derailed by the FDA, th...

Moderna targets $1.1 B in R&ampD costs cuts, falls 5 programs among productivity pressures

.Moderna has actually sworn to reduce R&ampD spending through $1.1 billion through 2027. The choice ...

Sanofi's $80M bank on Pivot dystrophy medication ends in stage 3 go under

.Simply 4 months after Sanofi wager $80 thousand in beforehand cash on Fulcrum Therapeutics' losmapi...